Heart failure is a progressive condition characterised by cardiomyocyte loss and cardiac fibroblast proliferation leading to cardiac hypertrophy and impaired heart function. Cardiac hypertrophy is commonly associated with high blood pressure in response to altered renin-angiotensin system (RAS) activity. However, there is evidence that RAS activity has a role in the early stages of heart failure that is independent of its influence on blood pressure. To investigate this, Justin F. X. Ainscough's group used a conditional mouse model in which a human angiotensin II type-I receptor transgene (HART) was expressed in fully matured cardiomyocytes. Persistent HART activity in young mice causes heart dysfunction without cardiac hypertrophy. This dysfunction correlates with increased expression of pro-angiogenic markers in cardiomyocytes and elicits a compensatory response in non-myocyte cells, which show downregulation of pro-angiogenic genes and inflammatory markers. Noteworthy, this stage is reversible by downregulation of HART expression. Further activation of the receptors, instead, leads to a secondary stage characterised by cardiomyocyte death and activation of fibroblast and inflammatory cells, which leads to further deterioration of heart function. This study therefore identifies an early stage of heart dysfunction associated with increased RAS activity, potentially treatable with RAS inhibitors to prevent heart failure development. Page 783
A reversible state of heart dysfunction treatable by RAS inhibition
- Split-screen
- Views Icon Views
-
Article Versions Icon
Versions
- Version of Record 01 August 2015
- Share Icon Share
-
Tools Icon
Tools
- Search Site
A reversible state of heart dysfunction treatable by RAS inhibition. Dis Model Mech 1 August 2015; 8 (8): e0803. doi:
Download citation file:
Advertisement
Cited by
Special Issue: The RAS Pathway

Our latest special issue is now complete. It showcases RAS-driven mechanisms of disease progression, and highlights approaches to treat and modify the disease course in model systems.
Call for papers: Moving Heart Failure to Heart Success

Disease Models & Mechanisms is pleased to welcome submissions for consideration for an upcoming special issue, Moving Heart Failure to Heart Success: Mechanisms, Regeneration & Therapy. The deadline for submitting articles to the special issue has been extended to 1 August 2022.
Propose a new Workshop

Our Workshops bring together leading experts and early-career researchers from a range of scientific backgrounds. Applications are now open to propose Workshops for 2024, one of which will be held in a Global South country. .
A focus on Drosophila

In a series of front section articles, DMM is highlighting the versatility, breadth, and scope of Drosophila research in human disease modelling and translational medicine.
Apply for a DMM Conference Travel Grant

Aimed at early-career researchers wanting to attend in-person and virtual meetings, the next application deadline for a DMM Conference Travel Grant is 6 June 2022. Find out more and hear from past recipients about their experience of the grant.
Other journals from
The Company of Biologists